These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 29048471)

  • 1. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
    Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
    Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
    Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
    J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.
    Lointier E; Cariou E; Beneyto M; Fournier P; Lavie-Badie Y; Eyharts D; Bureau C; Lairez O;
    Int J Cardiol; 2024 Dec; 416():132485. PubMed ID: 39187068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
    Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.
    Nitsche C; Ioannou A; Patel RK; Razvi Y; Porcari A; Rauf MU; Bandera F; Aimo A; Emdin M; Martinez-Naharro A; Venneri L; Petrie A; Wechalekar A; Lachmann H; Hawkins PN; Gillmore JD; Fontana M
    Eur J Heart Fail; 2024 Sep; 26(9):2008-2012. PubMed ID: 38922779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.
    Volpentesta E; Kharoubi M; Donadio C; Rebiai K; Fanen P; Funalot B; Gendre T; Audard V; Canoui-Poitrine F; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Tixier D; Mallet S; Broussier A; Damy T; Zaroui A
    ESC Heart Fail; 2024 Dec; 11(6):3814-3832. PubMed ID: 39021317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.
    Nakashima N; Takashio S; Morioka M; Nishi M; Yamada T; Hirakawa K; Ishii M; Tabata N; Yamanaga K; Fujisue K; Sueta D; Kanazawa H; Hoshiyama T; Hanatani S; Araki S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
    ESC Heart Fail; 2022 Jun; 9(3):1731-1739. PubMed ID: 35191205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
    ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Ladefoged B; Pedersen AD; Seefeldt J; Nielsen BRR; Eiskjær H; Lichscheidt E; Clemmensen T; Gillmore JD; Poulsen SH
    J Am Heart Assoc; 2024 Jul; 13(13):e034213. PubMed ID: 38934860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.